FDA Approves Novel Treatment for Plaque Psoriasis

May 24, 2022

Vtama® (tapinarof) 1% cream has been approved to treat plaque psoriasis in adults.

  • Vtama is the first novel topical treatment for plaque psoriasis to receive FDA approval in 25 It is also the first steroid-free topical medication in its class.
  • Recommended dosing is a thin layer of cream applied to the affected area once daily.
  • Manufacturer Dermavant Sciences has launched the product at a wholesale acquisition cost (WAC) of $1,325 per 60g tube.

Benefit Advisors & Employees - Want to know more?

Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager